Lilly Seeks Emergency Use of Its Antibody Drug for COVID-19
Early results from a study suggested the drug reduced symptoms, the amount of virus, hospitalizations, and ER visits for patients with mild or moderate COVID-19.
Related Articles
Could Paying for Obesity Medications Offset Obesity Care Costs?
With the Biden administration pushing for Medicare, Medicaid coverage of GLP-1s, analysts disagree on whether it will decrease obesity costs.
US Radiology Residencies: More Applicants Than Slots; Radiologist Shortage Persists
Interest is up for radiology residencies, but available positions don’t match demand. Radiologists say the problem can be fixed.
Goals of Analgesic Treatment: Understanding What’s Important in Acute and Chronic Pain
Did you know that establishing clear and measurable treatment goals can improve pain-related outcomes? Listen to our expert Dr Jeff Gudin to learn more.
Eye Toxicities Are a Growing Concern With Certain ADCs
Some antibody-drug conjugates may cause such significant ocular toxicity that patients have vision damage or have to stop treatment, yet many oncologists are unaware of…
Osteoporosis and Fractures: Prevention and Management
A comprehensive summary covering international recommendations on preventing and managing osteoporosis and fractures
Long-Acting Injectables In schizophrenia Part 3: Patient Treatment Journey
This interactive session will dive into how LAIs can significantly improve treatment adherence, provide greater stability, and enhance quality of life for in…
Does Exercise Really Boost Cognition?
The evidence suggests “yes,” “no,” and “maybe,” depending on who you ask. But most experts agree that better research is needed.
Clinical Advances in MASH: A Guide to Managing Metabolic Dysfunction-Associated Steatohepatitis
The incidence of MASH is on the rise. Learn more about determining risk in your patients and the new and emerging therapies available.
How Are Patients Managing Intermediate-Risk Prostate Cancer?
Adoption of active surveillance or watchful waiting has been increasing among patients with intermediate-risk prostate cancer between 2010 and 2020, a new analysis found.
The Road to Biosimilars in Rare Hematologic Conditions
Were you aware of the FDA’s Purple Book, an online database that contains information about biosimilar and interchangeable biological products approved by the FDA?